Merck is ending clinical development of nemtabrutinib after an external data monitoring committee reviewing the Phase 3 BELLWAVE-011 trial found that the investigational drug’s benefits may not outweigh its risks in the study. Merck said its own review of the full set of trial data confirmed the committee’s assessment and led it to stop the broader BELLWAVE development program.
The decision ends two other Phase 3 studies, BELLWAVE-008 and BELLWAVE-010, in addition to BELLWAVE-011. Merck had been evaluating nemtabrutinib in patients with chronic lymphocytic leukemia, small lymphocytic lymphoma and other blood cancers as part of the BELLWAVE program.
Nemtabrutinib, also known as MK-1026, is an investigational oral, noncovalent inhibitor of Bruton’s tyrosine kinase that suppresses cancer-related signaling through the B-cell receptor. In addition to the three Phase 3 trials, Merck evaluated the drug in BELLWAVE-001, BELLWAVE-003, BELLWAVE-015 and BELLWAVE-027, as well as in a study called waveLINE-006.
Merck said it is notifying investigators involved in the affected trials and advised patients to speak with their study teams and physicians about next steps and treatment options. Analyses of the trial data are continuing, and the company said it will share the results with the scientific community.
Merck said it will continue other research in blood cancers following the decision to end the nemtabrutinib program. Its broader hematology pipeline includes studies of investigational medicines both on their own and in combination with other therapies across a range of hematologic malignancies.
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from American Pharmaceutical Review – all delivered right to your inbox!
Sign up now!